Molecular Partners To Present Initial Data From Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At The 65th ASH Annual Meeting And Exposition
Portfolio Pulse from Benzinga Newsdesk
Molecular Partners has released initial data from its ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS. The preliminary data indicates an acceptable safety profile with no dose-limiting toxicity or severe adverse reactions. Five patients across three dosing regimens have been treated as of 20 July 2023.
November 02, 2023 | 7:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Molecular Partners' ongoing Phase 1/2a trial of MP0533 shows promising preliminary results, which could positively impact the company's stock.
The positive preliminary results from Molecular Partners' ongoing trial of MP0533 indicate a potential successful product in the pipeline. This could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100